The chief executive of the world's biggest maker of cancer drugs believes the drug approval process used by the UK's National Institute of Health and Care Excellence's needs revamping and that the country should look to Switzerland for a model to emulate.

Turku, Finland-based Faron Pharmaceuticals has floated on the London Stock Exchange's Alternative Investment Market (AIM), raising £10m to fund a Phase III trial for its lead product, orphan drug Traumakine.

Seven months into the job and the shine is wearing off Sanofi's new CEO Olivier Brandicourt. His first 'Meet the Management' investor day on Nov. 6 left analysts underwhelmed and shares slipping.

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has found no evidence to support a causal link between the marketed HPV vaccines and two rare conditions after a review of the latest scientific knowledge.